Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Long-Term Investments (2021 - 2025)

Caribou Biosciences has reported Long-Term Investments over the past 5 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Long-Term Investments fell 62.21% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 62.21% year-over-year, with the annual reading at $3.5 million for FY2025, 62.21% down from the prior year.
  • Long-Term Investments was $3.5 million for Q4 2025 at Caribou Biosciences, down from $12.0 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $62.5 million in Q1 2023 and troughed at $132000.0 in Q2 2025.
  • The 5-year median for Long-Term Investments is $9.3 million (2025), against an average of $21.6 million.
  • Year-over-year, Long-Term Investments soared 714.66% in 2023 and then tumbled 99.74% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $37.7 million in 2021, then tumbled by 79.57% to $7.7 million in 2022, then surged by 466.08% to $43.6 million in 2023, then crashed by 78.71% to $9.3 million in 2024, then tumbled by 62.21% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Long-Term Investments are $3.5 million (Q4 2025), $12.0 million (Q3 2025), and $132000.0 (Q2 2025).